UGN-102 联合或不联合经尿道膀胱肿瘤电切术对比经尿道膀胱肿瘤电切术单药治疗低级别中危非肌层浸润性膀胱癌:一项随机对照3期试验(ATLAS)
ATLAS 是一项前瞻性随机3期试验,纳入282例新发或复发性低级别中危非肌层浸润性膀胱癌患者,比较 UGN-102(含丝裂霉素的反向热凝胶)膀胱内化学消融联合或不联合经尿道膀胱肿瘤电切术与单纯经尿道膀胱肿瘤电切术的疗效与安全性。因申办方提前终止入组,试验检验效能不足。初始治疗后3个月无瘤完全缓解率 UGN-102 组为65%、经尿道膀胱肿瘤电切术组为64%;随机化后15个月无病生存估计概率分别为72%和50%(风险比0.45)。
要点
- UGN-102组3个月无瘤完全缓解92例(65%),经尿道膀胱肿瘤电切术组89例(64%)。
- 15个月无病生存估计概率 UGN-102±经尿道膀胱肿瘤电切术组72%,经尿道膀胱肿瘤电切术组50%(风险比0.45)。
- 因申办方提前终止入组,实际随机282例(计划632例),试验检验效能不足。
核心结论
- 作者认为,UGN-102 原发非手术化学消融治疗低级别中危非肌层浸润性膀胱癌,为即刻经尿道膀胱肿瘤电切术单药治疗提供了一种潜在的治疗替代选择,值得进一步研究。
研究设计与样本
- 前瞻性、随机、3期试验,计划随机632例,实际随机282例新发或复发性低级别中危非肌层浸润性膀胱癌患者。
- 患者随机接受 UGN-102 每周一次共6周的初始治疗(联合或不联合后续经尿道膀胱肿瘤电切术,n=142)或经尿道膀胱肿瘤电切术单药治疗(n=140)。
- 患者每季度接受内镜、细胞学检查及按需活检随访,主要终点为无病生存,所有患者均随访不良事件。
- 入组在282例随机化后被申办方终止以寻求替代开发策略,试验检验效能不足以进行假设检验。
主要发现
- 初始治疗后3个月无瘤完全缓解:UGN-102组92例(65%),经尿道膀胱肿瘤电切术组89例(64%)。
- 随机化后15个月无病生存估计概率:UGN-102±经尿道膀胱肿瘤电切术组72%,经尿道膀胱肿瘤电切术组50%(风险比0.45)。
- UGN-102组最常见不良事件(发生率≥10%)为排尿困难、尿急、夜尿和尿频。
- 患者以男性为主且年龄≥65岁。
临床怎么用
- 作者认为,UGN-102 原发非手术化学消融可为低级别中危非肌层浸润性膀胱癌提供一种潜在的治疗替代选择,值得进一步研究。
局限性
- 入组在282例随机化后被申办方终止以寻求替代开发策略,试验检验效能不足以进行假设检验。
- 作者在结论中提出该治疗选择值得进一步研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Low-grade intermediate-risk nonmuscle-invasive bladder cancer is a chronic illness commonly treated by repetitive transurethral resection of bladder tumor. We compared the efficacy and safety of intravesical chemoablation with UGN-102 (a reverse thermal gel containing mitomycin), with or without subsequent transurethral resection of bladder tumor, to transurethral resection of bladder tumor alone in patients with low-grade intermediate-risk nonmuscle-invasive bladder cancer. MATERIALS AND METHODS: This prospective, randomized, phase 3 trial recruited patients with new or recurrent low-grade intermediate-risk nonmuscle-invasive bladder cancer to receive initial treatment with either UGN-102 once weekly for 6 weeks or transurethral resection of bladder tumor. Patients were followed quarterly by endoscopy, cytology, and for-cause biopsy. The primary end point was disease-free survival. All patients were followed for adverse events. RESULTS: Trial enrollment was halted by the sponsor to pursue an alternative development strategy after 282 of a planned 632 patients were randomized to UGN-102 ± subsequent transurethral resection of bladder tumor (n=142) or transurethral resection of bladder tumor monotherapy (n=140), rendering the trial underpowered to perform hypothesis testing. Patients were predominantly male and ≥65 years of age. Tumor-free complete response 3 months after initial treatment was achieved by 92 patients (65%) who received UGN-102 and 89 patients (64%) treated by transurethral resection of bladder tumor. The estimated probability of disease-free survival 15 months after randomization was 72% for UGN-102 ± transurethral resection of bladder tumor and 50% for transurethral resection of bladder tumor (hazard ratio 0.45). The most common adverse events (incidence ≥10%) in the UGN-102 group were dysuria, micturition urgency, nocturia, and pollakiuria. CONCLUSIONS: Primary, nonsurgical chemoablation with UGN-102 for the management of low-grade intermediate-risk nonmuscle-invasive bladder cancer offers a potential therapeutic alternative to immediate transurethral resection of bladder tumor monotherapy and warrants further investigation.
引用
- Prasad SM, Huang WC, Shore ND, et al. Treatment of Low-grade Intermediate-risk Nonmuscle-invasive Bladder Cancer With UGN-102 ± Transurethral Resection of Bladder Tumor Compared to Transurethral Resection of Bladder Tumor Monotherapy: A Randomized, Controlled, Phase 3 Trial (ATLAS). J Urol. 2023. PMID: 37548555. doi:10.1097/JU.0000000000003645
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。